NeurAxis, Inc. (NRXS)
| Market Cap | 87.93M +596.1% |
| Revenue (ttm) | 3.57M +32.9% |
| Net Income | -8.62M |
| EPS | -0.95 |
| Shares Out | 11.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 530,574 |
| Open | 7.84 |
| Previous Close | 7.45 |
| Day's Range | 7.77 - 8.40 |
| 52-Week Range | 1.94 - 8.40 |
| Beta | 1.89 |
| Analysts | Strong Buy |
| Price Target | 13.00 (+65.39%) |
| Earnings Date | May 12, 2026 |
About NRXS
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation di... [Read more]
Financial Performance
In 2025, NeurAxis's revenue was $3.57 million, an increase of 32.89% compared to the previous year's $2.69 million. Losses were -$8.62 million, 1.92% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for NRXS stock is "Strong Buy" and the 12-month stock price target is $13.0.
News
NeurAxis Expands Payer Coverage with Four New Medical Policies
CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...
NeurAxis, Inc. Announces Preferred Stock Dividend
CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
NeurAxis Earnings Call Transcript: Q4 2025
Q4 and FY 2025 saw double-digit revenue growth, expanded payer coverage, and operational milestones, with over 100 million covered lives and a new CPT code driving adoption. Gross margins remain strong, and liquidity is sufficient for growth, with further upside expected as policy coverage expands.
NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
NeurAxis Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
Significant milestones include a new Category I CPT code, expanded insurance coverage, and strong clinical data supporting a non-drug device for pediatric and adult GI disorders. Financials show solid margins and a clear path to profitability, with a focus on scaling coverage and revenue.
NeurAxis Earnings Call Transcript: Q3 2025
Q3 2025 saw 22% revenue growth and the fifth straight quarter of double-digit gains, driven by IB-STIM adoption and FDA label expansion. The new Category 1 CPT code effective in 2026 is expected to accelerate adoption and improve margins, with cash runway into H2 2026.
NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues
Conference call will be held today, Tuesday, November 11 at 9:00 am ET Conference call will be held today, Tuesday, November 11 at 9:00 am ET
NeurAxis Transcript: Lytham Partners Fall 2025 Investor Conference
IB-Stim is the first FDA-cleared treatment for pediatric functional abdominal pain and dyspepsia, addressing a major unmet need. With new NASPGHAN guideline support, a Category I CPT code effective January 2026, and expanding insurance coverage, significant market penetration and revenue growth are expected.
NeurAxis Earnings Call Transcript: Q2 2025
Q2 2025 saw 46% revenue growth, major milestones including FDA indication expansion, and assignment of a favorable Category I CPT code. Gross margin declined due to discounting, but profitability and cash flow breakeven remain on track as insurance coverage expands and new policies take effect.
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives
CARMEL, Ind., June 17, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...
NeurAxis Transcript: Lytham Partners Spring 2025 Investor Conference
A neuromodulation company is expanding its pediatric GI therapy indications, supported by strong clinical data, a new Category 1 CPT code effective in 2026, and growing insurance coverage. Recent capital raises ensure over a year of runway as the company prepares for major growth catalysts.
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering
CARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ch...
NeurAxis Announces $5.0 Million Registered Direct Offering
CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ch...
NeurAxis Earnings Call Transcript: Q1 2025
Double-digit revenue growth continued in Q1 2025, driven by IB-Stim and RED, with expanding insurance coverage and a new Category I CPT code set to accelerate future growth. Gross margin remains strong, and cash flow break-even is targeted as key academic guidelines and policy coverage are expected soon.
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic a...
NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025
Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time Financial results to be released before market open; Conference call to be conducted at 9...
NeurAxis Transcript: Planet MicroCap Showcase: VEGAS 2025
Achieved a key regulatory milestone with a category one CPT code effective 2026 and expanded insurance coverage to 51 million lives. Strong clinical data and a growing pipeline support significant market opportunity, with profitability in sight and new product launches underway.
NeurAxis Earnings Call Transcript: Q4 2024
Q4 2024 saw 43% revenue growth and expanded insurance coverage to 51 million lives. Category I CPT code and FDA label expansion position the company for accelerated growth, with breakeven targeted at $10–$12 million in annual revenue.
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025
CARMEL, Ind., March 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States
CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States
CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...
NeurAxis Transcript: Lytham Partners 2025 Investor Healthcare Summit
A med tech firm with two FDA indications and a flagship pediatric device is rapidly expanding insurance coverage and achieved a category one CPT code effective January 2026. Q3 and Q4 2024 saw revenue growth of 40% and 50%, with further growth expected as insurance and reimbursement milestones are met.
NeurAxis Inc. Issues Letter to Shareholders
CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
CARMEL, Ind., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing c...